{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:06:08Z","timestamp":1779203168876,"version":"3.51.4"},"reference-count":47,"publisher":"American Society for Clinical Investigation","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,8]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND.<\/jats:bold>\n                    Immune checkpoint blockade improves survival in a subset of patients with non\u2013small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 pathway inhibitors are lacking. Furthermore, our understanding of the diversity of the NSCLC tumor immune microenvironment remains limited.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS.<\/jats:bold>\n                    We performed comprehensive flow cytometric immunoprofiling on both tumor and immune cells from 51 NSCLCs and integrated this analysis with clinical and histopathologic characteristics, next-generation sequencing, mRNA expression, and PD-L1 immunohistochemistry (IHC).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS.<\/jats:bold>\n                    Cytometric profiling identified an immunologically \u201chot\u201d cluster with abundant CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells expressing high levels of PD-1 and TIM-3 and an immunologically \u201ccold\u201d cluster with lower relative abundance of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and expression of inhibitory markers. The \u201chot\u201d cluster was highly enriched for expression of genes associated with T cell trafficking and cytotoxic function and high PD-L1 expression by IHC. There was no correlation between immunophenotype and KRAS or EGFR mutation, or patient smoking history, but we did observe an enrichment of squamous subtype and tumors with higher mutation burden in the \u201chot\u201d cluster. Additionally, approximately 20% of cases had high B cell infiltrates with a subset producing IL-10.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS.<\/jats:bold>\n                    Our results support the use of immune-based metrics to study response and resistance to immunotherapy in lung cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>FUNDING.<\/jats:bold>\n                    The Robert A. and Ren\u00e9e E. Belfer Family Foundation, Expect Miracles Foundation, Starr Cancer Consortium, Stand Up to Cancer Foundation, Conquer Cancer Foundation, International Association for the Study of Lung Cancer, National Cancer Institute (R01 CA205150), and the Damon Runyon Cancer Research Foundation.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.89014","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T11:01:49Z","timestamp":1473246109000},"source":"Crossref","is-referenced-by-count":109,"title":["Multiparametric profiling of non\u2013small-cell lung cancers reveals distinct immunophenotypes"],"prefix":"10.1172","volume":"1","author":[{"given":"Patrick H.","family":"Lizotte","sequence":"first","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena V.","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Jones","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Keogh","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongye","family":"Liu","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Dries","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-1342","authenticated-orcid":true,"given":"Christina","family":"Almonte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit S.","family":"Herter-Sprie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora B.","family":"Feeney","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghana M.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Bass","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Rustgi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Departments of Medicine and Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Cheng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Chan School of Public Health, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald W.","family":"Kufe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Hammerman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Department of Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Richards","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Division of Thoracic Surgery, and"},{"name":"International Mesothelioma Program of the Lung Center Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Division of Thoracic Surgery, and"},{"name":"International Mesothelioma Program of the Lung Center Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie M.","family":"English","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Bittinger","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[{"name":"Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA."},{"name":"Department of Medical Oncology and"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"232","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"issue":"17","key":"B1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"B2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"B3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","unstructured":"EER Stat Fact Sheets: Lung and Bronchus Cancer. National Cancer Institute. http:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html Accessed August 30, 2016"},{"issue":"3","key":"B5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"B7","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7528","key":"B8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"19","key":"B9","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"B10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 Expression in Lung Cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"B12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00408-013-9455-7","article-title":"Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer","volume":"191","author":"Black","year":"2013","journal-title":"Lung"},{"issue":"1","key":"B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.humimm.2015.10.015","article-title":"Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in non small cell lung carcinoma patients","volume":"77","author":"Liu","year":"2016","journal-title":"Hum Immunol"},{"issue":"4","key":"B14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/15384047.2016.1156256","article-title":"PD-1\/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR\/KRAS mutations","volume":"17","author":"Ji","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"B15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","article-title":"Lung cancer: epidemiology, etiology, and prevention","volume":"32","author":"Dela Cruz","year":"2011","journal-title":"Clin Chest Med"},{"issue":"6280","key":"B16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"1","key":"B17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","article-title":"The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures","volume":"39","author":"Galon","year":"2013","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-015-0088-7","article-title":"nCounter(\u00ae) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)","volume":"3","author":"Cesano","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B19","unstructured":"Murtagh F. Multidimensional Clustering Algorithms. Fionn Murtagh. http:\/\/www.multiresolutions.com\/strule\/old-articles\/MultidimensionalClusteringAlgorithms_FMurtagh.pdf Accessed: August 9, 2016"},{"issue":"3","key":"B20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","article-title":"Ward\u2019s hierarchical agglomerative clustering method: which algorithms implement Ward\u2019s criterion?","volume":"31","author":"Murtagh","year":"2014","journal-title":"J Classif"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2342"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0184"},{"issue":"1","key":"B23","first-page":"3221","article-title":"Accelerating t-SNE Using Tree-based Algorithms","volume":"15","author":"Van Der Maaten","year":"2014","journal-title":"J Mach Learn Res"},{"key":"B24","doi-asserted-by":"crossref","unstructured":"Frampton GM, et al. Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. ASCO University. http:\/\/meetinglibrary.asco.org\/content\/167202-176 Accessed August 9, 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.11558"},{"issue":"11","key":"B25","first-page":"112","article-title":"[Chromosomal damage in a series of cell generations following application of rubomycin C to cultured human cells]","volume":"73","author":"Sinkus","year":"1972","journal-title":"Biull Eksp Biol Med"},{"issue":"2","key":"B26","first-page":"136","article-title":"[Congenital abnormalities of the uterus]","volume":"13","author":"Ananiev","year":"1974","journal-title":"Akush Ginekol (Sofiia)"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00067","article-title":"Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity","volume":"6","author":"Germain","year":"2015","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.10.007"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.006"},{"issue":"7505","key":"B30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nature13437","article-title":"Single-cell RNA-seq reveals dynamic paracrine control of cellular variation","volume":"510","author":"Shalek","year":"2014","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000687"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3362"},{"key":"B33","article-title":"EGFR mutations and alk rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): A Retrospective Analysis","journal-title":"Clin Cancer Res"},{"issue":"1","key":"B34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/107327481402100112","article-title":"Update on immune checkpoint inhibitors in lung cancer","volume":"21","author":"Creelan","year":"2014","journal-title":"Cancer Control"},{"issue":"2 Supplement","key":"B35","first-page":"A20","article-title":"Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4161\/onci.25443"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1408"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2482"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26836"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2639"},{"key":"B42","doi-asserted-by":"crossref","first-page":"4.22.1","DOI":"10.1002\/0471142727.mb0422s107","article-title":"Preparation of single-cell RNA-Seq libraries for next generation sequencing","volume":"107","author":"Trombetta","year":"2014","journal-title":"Curr Protoc Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-4-r36"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp120"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/89014\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:20:53Z","timestamp":1779200453000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/89014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":47,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2016,9,8]]},"published-print":{"date-parts":[[2016,9,8]]}},"alternative-id":["10.1172\/jci.insight.89014"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.89014","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]},"article-number":"e89014"}}